Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

In the era of new and mostly effective therapeutic protocols, multiple myeloma still tends to
be a hard-to-treat hematologic cancer. This hallmark of the disease is in fact a sequel to drug …

Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a
cornerstone position in the treatment of hematological malignancies, particularly multiple …

Despite significant advances in cancer diagnostics and therapeutics the majority of cancer
unfortunately remains incurable, which has led to continued research to better understand …

The emergence of multidrug resistance (MDR) is among the crucial obstacles to breast
cancer therapy success. The transcription factor nuclear factor (NF)-κB is correlated to the …

Current treatment strategies for rheumatoid arthritis (RA) consisting of disease-modifying
anti-rheumatic drugs or biological agents are not always effective, hence driving the demand …

Proteasome inhibitors have shown relevant clinical activity in several hematological
malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient …

Multiple myeloma is a malignant plasma cell neoplasm that remains incurable and is
ultimately fatal when patients acquire multi-drug resistance. Thus, advancing our …

Multiple myeloma (MM) is a malignant neoplastic cancer of the plasma cells that involves the
bone marrow. The majority of patients with MM initially respond to chemotherapy, but they …

The occurrence of efflux mechanisms via Permeability-glycoprotein (P-gp) recognized as an
important physiological process impedes drug entry or transport across membranes into …